Natera, Inc. (NTRA)
Sector: Healthcare
Industry: Services-Medical Laboratories
Country: United States
Exchange: NASDAQ
Market cap: $52.80B
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Latest financial period: June 30, 2026
Filed with the SEC: August 7, 2026
Estimated earnings date: November 5, 2026
Profit #1303 of 1484 companies
| | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|
| ROE/ROA | 9.6% | 10.0% | 10.1% | 7.6% |
Growth #217 of 1484 companies
Payout #1117 of 1484 companies
Safety #58 of 1484 companies
Price #1325 of 1484 companies
